Krystal Biotech (NASDAQ:KRYS) Earns Buy Rating from HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $310.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 0.31% from the stock’s current price.

A number of other research analysts have also weighed in on KRYS. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Guggenheim raised their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Jefferies Financial Group raised their price objective on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Citigroup raised their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Finally, Chardan Capital raised their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Ten investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Krystal Biotech presently has an average rating of “Moderate Buy” and an average price target of $324.11.

Krystal Biotech Price Performance

KRYS opened at $309.03 on Monday. The company’s 50-day moving average is $277.59 and its 200 day moving average is $261.20. Krystal Biotech has a fifty-two week low of $123.03 and a fifty-two week high of $319.48. The firm has a market capitalization of $9.11 billion, a P/E ratio of 41.31 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. On average, equities research analysts expect that Krystal Biotech will post 7.83 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the completion of the sale, the insider owned 1,403,155 shares in the company, valued at approximately $369,324,427.55. This trade represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP John Charles Thomas sold 642 shares of Krystal Biotech stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total transaction of $193,903.26. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Large investors have recently modified their holdings of the business. Western Wealth Management LLC purchased a new position in shares of Krystal Biotech in the first quarter worth about $34,000. Greenline Wealth Management LLC purchased a new position in shares of Krystal Biotech in the fourth quarter worth about $34,000. Sound Income Strategies LLC increased its stake in shares of Krystal Biotech by 1,270.0% in the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares in the last quarter. Finally, Bessemer Group Inc. increased its stake in shares of Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after purchasing an additional 77 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.